Many severe diseases are located in deep tissues or behind biological barriers that standard systemic drugs cannot penetrate effectively. This anatomical challenge severely limits therapeutic efficacy for conditions affecting the central nervous system, solid tumors, and other immunologically privileged sites. Systemic therapies (such as chemotherapy) produce severe adverse effects while remaining limited in efficacy due to insufficient drug concentration at target sites. The lack of selective delivery mechanisms forces clinicians to use higher systemic doses to achieve therapeutic concentrations locally, resulting in widespread toxicity to healthy tissues and dose-limiting side effects that compromise patient tolerance and treatment outcomes.

Technology
The platform incorporates a unique combination of complementary technologies:

• Biocompatible magnetic nanoparticle synthesis enables the generation of iron oxide or other biocompatible nanomaterials that can be safely administered systemically while minimizing immunogenic responses
• External magnetic field control for targeted navigation allows precise directional guidance of nanoparticles to diseased tissues through applied magnetic gradients, enabling non-invasive spatial control without requiring implanted devices
• Site-specific activation capability at disease locations provides triggered release or activation of therapeutic payloads only at target sites, reducing off-target effects and maximizing local concentration

Figure 1. Experimental concept. (Left) CD synthesis followed by mesoporous vaterite encapsulation. (Middle) Vaterite particles loaded with CDs. (Top right) Illustration of glioma cells incubated with fluorescent particles excited with a NIR femtosecond laser. (Bottom right) Illustration of in vivo imaging of CD−vaterite composites circulating in the brain vasculature.

Potential Applications
The platform enables minimally invasive, on-demand therapeutic activation for:

• Localized diagnostic imaging with enhanced contrast and reduced background noise compared to conventional imaging agents
• Drug delivery to anatomically challenging tissue sites including the brain, retina, and other hard-to-reach compartments
• Real-time theranostic monitoring and feedback combining simultaneous diagnosis and therapy with the ability to monitor treatment response in real time

Stage
Multiple funded projects are currently in the in vitro proof-of-concept phase, validating core functionality and establishing preliminary safety and efficacy parameters before advancing to animal model studies.

References:
1. Ushkov et al (2025), Laser & Photonics Reviews
2. Barhum et al(2024), Chemical Engineering Journal 
3. Barhum et al(2024), Nano Letters 
4. Noskov et al (2021),  Advanced Materials